Clinical Management of Infant Anaphylaxis

Annette Carlisle
Jay Lieberman
Department of Pediatrics, Division of Pediatric Pulmonary, Sleep, Allergy & Immunology, The University of Tennessee Health Science Center, Le Bonheur Children’s Hospital, Memphis, TN, USA

Abstract: Anaphylaxis is a condition that is likely increasing in prevalence and commonly treated by allergists as well as other first responders and emergency room providers. Although a relatively rare event, anaphylaxis can occur in infants, with the most common cause attributed to foods. Infant anaphylaxis can present with unique diagnostic challenges and treatment considerations. While infants can present with classic signs and symptoms of anaphylaxis (eg, urticaria, angioedema, dyspnea, wheeze, and vomiting) they can also present with non-classical signs. Non-classical signs of infant anaphylaxis can include ear pulling, tongue thrusting, fussiness, and increase clinginess to the caregiver. These non-classic signs of infant anaphylaxis can often mimic normal infant behavior further complicating the diagnosis. Additionally, when treating infant anaphylaxis, there are special considerations regarding the use of epinephrine. These include determining appropriate needle length, dosages appropriate to administer depending on the weight of the infant, and the availability of different epinephrine auto-injectors. In this article, we aim to review the clinical management of infant anaphylaxis including diagnosis, recognition, treatment, strategies for follow-up and special considerations regarding epinephrine administration in this demographics.

Keywords: infant anaphylaxis, epinephrine

Introduction
Anaphylaxis is a common condition with an estimated prevalence of at least 1.6% in the United States and this is likely increasing.1 Despite anaphylaxis being a cornerstone of allergy training, the diagnosis can often be difficult and there can often be lack of agreement.2 And while all major guidelines agree that epinephrine is the treatment of choice, there continue to be barriers to its widespread use.3 Unfortunately, diagnosis and management of infant anaphylaxis can present even more unique challenges than in older ages due to difficult clinical presentation and unique challenges to epinephrine administration (Figure 1). Thus, it is important for providers to be well versed in the management of infant anaphylaxis including proper diagnosis, recognition, acute management, long-term follow up and special considerations about epinephrine. We aim to review the current literature regarding clinical management of infant anaphylaxis. We completed a comprehensive PubMed search using the key search terms “clinical management of infant anaphylaxis.” We also searched using synonyms for infants (toddler, baby, age up to three years old), anaphylaxis (allergic reaction, epinephrine, epinephrine auto-injector use, anaphylactic shock, hypersensitivity reaction, pediatric anaphylaxis), and clinical management (medical management). The search produced approximately 300 articles. Full texts were screened with emphasis placed on high-quality studies (reviews, consensus statements). Additional references were...
Prevalence
The prevalence of infant anaphylaxis is largely unknown but overall it is rare. For example, in the European Anaphylaxis Registry, infants <1 year of age only accounted for 18 out of a total of 1970 (0.9%) cases in an anaphylaxis cohort of children and adolescents. This is less than would be expected by natural distribution of age. Data suggest though that the number of cases is increasing similar to known increases in food allergy prevalence over recent years. Between 2007 and 2012, food induced anaphylaxis prevalence increased 50% in ages 6 months to 18 years. A review of food-induced anaphylaxis cases at two Boston children’s hospitals found 29% of patients presenting were less than two years old. Dyer et al noted between 2008 and 2012 there was an annual increase of 27% of food-induced anaphylaxis cases in children ages 0–4. Thus, given the increasing number of food-induced anaphylaxis cases in all ages, it is possible that the number of infant anaphylaxis cases will simply mirror this increase. However, with new data showing the benefit of early introduction of allergenic foods on the overall prevalence of food allergy, it is reasonable to expect an increase in food-induced allergic reactions in infants who would not have been fed the food in years past based on former recommendations. Thus, it is very likely that over time, more and more infants will be fed allergenic foods, which should decrease overall food allergy prevalence, but may also in time lead to more frequent infant allergic reactions.

Diagnosis
Although an infant-specific diagnostic algorithm for anaphylaxis has not been developed, the recently published expert panel consensus by Greenhawt et al suggests using the current NIAID/FAAN definition to define potential cases. According to the NIAID/FAAN criteria, anaphylaxis is highly likely when any one of the three criteria are met: 1) Acute onset of illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both and at least one of the following: respiratory compromise or reduced blood pressure. 2) Two or more of the following that occur rapidly after exposure to a likely allergen for

---

**Figure 1** Review of unique aspects regarding management of infant anaphylaxis.
that patient (minutes to hours): involvement of the skin-mucosal tissue, respiratory compromise, reduced blood pressure or associated symptoms, or persistent vomiting. 3) reduced blood pressure after exposure to a known allergen for that patient (minutes to hours) defined as low systolic BP based on age or greater than 30% decrease in systolic BP or systolic <90mmHg or greater than 30% decrease from baseline as adults.\textsuperscript{14}

Infant anaphylaxis can be triggered by a variety of agents but most often is due to foods. Specifically, cow’s milk, egg, peanut, and tree nuts have been recognized as the most common culprits worldwide.\textsuperscript{4,5,15–17} Less common agents implicated include drugs (antibiotics, antipyretics, neuromuscular blockers, etc), vaccines, insect stings, natural rubber latex, and topical agents; however, these are very rare triggers in infants.\textsuperscript{18,19} Idiopathic anaphylaxis has even been reported in infants, but once again, this is a rare cause.\textsuperscript{20} Fortunately, severe anaphylaxis and biphasic reactions are less commonly reported.\textsuperscript{4} Co-morbidities increasing the risk of severe infant anaphylaxis are not well defined in infants although it has been suggested that co-morbid conditions including croup, bronchiolitis, asthma, and atopic dermatitis could potentially increase risk.\textsuperscript{4,18} Known peanut and tree nut allergy have also been found to be risk factors for severe reactions.\textsuperscript{17,21}

Additionally, it has been postulated that co-factors in infant anaphylaxis could be similar as in other age groups including fever, upper respiratory tract infection, and emotional stress. However, no infant-specific studies support what co-morbidities or co-factors play a role and further research is needed in these areas.\textsuperscript{22–24}

Recognition of infant anaphylaxis resembles recognition of anaphylaxis in other age groups. In the appropriate clinical context, anaphylaxis will most likely include cutaneous (generalized urticaria, flushing, angioedema), gastrointestinal (persistent vomiting), cardiovascular (tachycardia, hypotension), respiratory (cough, wheeze, stridor) and/or behavioral changes.\textsuperscript{18} In infants specifically, several studies have demonstrated cutaneous symptoms are the most common followed by gastrointestinal and respiratory symptoms; cardiovascular symptoms (eg, hypotension) are rarely reported.\textsuperscript{5,10,25} Furthermore, hypotension may be a late sign of infant anaphylaxis compared to adults while tachycardia may be an early indicator of cardiovascular involvement in infants, although this may represent common routes of exposure of the antigen in these age groups (ie, venom stings and parenteral medications are likely to lead to early hypotension, and this is simply seen more often in adults than infant).

Diagnostic challenges can often arise as infants are non-verbal and allergic symptoms can overlap normal infant behavior or symptoms that overlap with other pediatric conditions (Table 1). For example, infants cannot verbally describe several symptoms associated with anaphylaxis such as difficulty breathing, pruritus, throat closure sensation, feeling faint, or sense of impending doom. Furthermore, several infant behaviors including clinging to the caregiver, cessation of playing, crying, spitting up/ regurgitation after foods, increased secretions, loose stools, sleepiness/drowsiness after feeds, flushing with fever or crying spells, scratching, and irritability can all be normal behaviors, leading to misdiagnosis of anaphylaxis if inappropriately interpreted depending on the clinical context.\textsuperscript{4,18} For example, in one survey study of caregivers, infants who had anaphylaxis had reported signs such as eye rubbing in about 40% of cases and ear pulling in about 16% of cases.\textsuperscript{26} In addition to normal infant behavior or anaphylaxis, other differentials such as the one published by Simons & Sampson must be considered.\textsuperscript{18} These include skin manifestations related to underlying viral exanthem or hereditary angioedema, congenital respiratory anomalies, breath holding spells, gastrointestinal tract obstruction, gastrointestinal anatomic abnormalities such as pyloric stenosis or malrotation, food protein-induced enterocolitis, various forms of shock not due to anaphylaxis, central nervous system issues such as seizure disorder, other infectious-disease-

### Table 1 Signs of Infant Anaphylaxis\textsuperscript{4,18,26}

<table>
<thead>
<tr>
<th>Classic Symptoms</th>
<th>Non-Classic Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin: hives, rashes, itching, angioedema</td>
<td>Skin: eye rubbing, eye itching, ear scratching, tongue thrusting, tongue pulling, repetitive lip licking or licking of hands</td>
</tr>
<tr>
<td>GI: vomiting, diarrhea, abdominal pain</td>
<td>GI: spitting up, back arching, bringing knees to chest, hiccup</td>
</tr>
<tr>
<td>Respiratory: cough, wheeze, tachypnea</td>
<td>Respiratory: hoarse voice/cry, putting fingers in ears, ear pulling</td>
</tr>
<tr>
<td>CV: hypotension, fainting</td>
<td>CV: skin motting</td>
</tr>
<tr>
<td>Neuro: crankiness, inconsolable crying, withdrawn/clingy</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Data from Greenhawt et al\textsuperscript{4}, Simons et al\textsuperscript{18}, Pistiner et al\textsuperscript{26}.
related presentations, ingestions, as well as others.\textsuperscript{16} When diagnosing infant anaphylaxis, it is crucial to obtain a thorough history in order to tease out the subtleties that would suggest true anaphylaxis versus another cause.

Work up of infant anaphylaxis in the acute setting should parallel previously published guidelines focusing on acute treatment as well as identification of a possible allergic trigger.\textsuperscript{27,28} Prompt evaluation including obtaining vital signs and history noting potential triggers should be obtained. While obtaining the history, it is critical to pay attention to the timing of symptoms as IgE-mediated reactions occur within minutes and rarely after two hours. Unfortunately, there is no biomarker with high sensitivity and specificity for anaphylaxis, especially in food allergic reactions, which are the most common in infants.\textsuperscript{4} Within two to four hours of the inciting incident, mast cell tryptase can be considered. Mast cell tryptase must be obtained within this time frame as outside of this window the value is mostly reflective of the resting burden of mast cells and not necessarily clinically useful unless underlying mast cell disease.\textsuperscript{29} Additionally, with food induced anaphylaxis mast cell tryptase may not always be elevated.\textsuperscript{22} Thus, while a highly elevated tryptase in the acute setting can be helpful, a low tryptase may not necessarily exclude anaphylaxis particularly with foods. Once the patient is stable for discharge, caregivers should be instructed to avoid the possible causative trigger, prescribed an epinephrine auto-injector and instructed on indications and how to administer given that most cases of infant anaphylaxis as well as episodes of recurrent anaphylaxis occur at home. The possibility of recurrent anaphylaxis and known risk factors should also be discussed with families. Patients follow-up with an allergist for further work-up is also recommended.\textsuperscript{28} Unfortunately, this may not always be frequently done. For example, Wright et al showed that at one pediatric hospital that has an associated allergy division, only 30% of confirmed pediatric anaphylaxis cases in their ED were referred to an allergist, and only 10% actually saw the allergist.\textsuperscript{30}

In the outpatient setting after the initial reaction, obtaining a history remains critically important. During the history, the time course as well as potential triggers and co-factors should be documented. Based on the history, work-up in the outpatient setting can include skin prick testing or if skin prick testing is unavailable serum IgE testing can be completed to detect sensitization to potential triggers. Testing should be dictated by history, and the authors do not recommend performing food panel testing. If the initial testing was negative but strong clinical suspicion of anaphylaxis exists, one can consider repeating the testing for suspected triggers in four to six weeks with continued avoidance until repeat testing.\textsuperscript{18} This is due to the fact it can take four to six weeks from the initial mast cell degranulation for skin testing to be positive. Once allergic triggers are identified based on history and/or testing, families should be educated on avoidance and proper use of the epinephrine auto-injector.\textsuperscript{4}

**Treatment**

Treatment of infant anaphylaxis, as with anaphylaxis in any age group, should begin promptly with the administration of epinephrine. Unfortunately, infants may be at an even greater risk than other ages for delayed epinephrine administration due ambiguity in infant symptoms and their mimicking normal infant behavior.\textsuperscript{31} Furthermore, several studies have shown that there is delayed epinephrine use in both the healthcare and home setting, and thus all parties should be comfortable with administering epinephrine for improved outcomes.\textsuperscript{3,30,32} In the home setting, it has been reported that parents are often fearful to give epinephrine or were unsure whether or not epinephrine should be administered.\textsuperscript{30,33} If an infant is at home, where anaphylaxis is most likely to occur, and there is concern for anaphylaxis, it is important that caregivers are educated on the proper management including being comfortable with epinephrine administration. Additional treatment strategies include removal of any suspected trigger, rapid assessment of airway, breathing, and circulation as well as prompt administration of epinephrine using an auto-injector.\textsuperscript{18} Caregivers should also understand they can give multiple doses every three to five minutes if needed and understand the importance of either calling 911 or going to the emergency department for further evaluation, treatment, and monitoring in case of a severe reaction.

For management in the health care setting, many of the same steps apply (Figure 2).\textsuperscript{18} Initially, remove any suspected trigger. Rapidly assess airway, breathing, circulation, skin and record patient’s weight. The infant should be placed in a supine or semi-reclining position in the caregiver’s arms. In infants with suspected anaphylaxis or severe allergic reaction, inject epinephrine intramuscularly at a dose of 0.01mg/kg or use an epinephrine auto-injector (0.15mg or 0.1mg) in the community setting (dosing discussed further below). The auto-injectors can be used in the health care setting as well as some institutions may find them more convenient than using epinephrine vials.
and syringes which require using filter needles and drawing up exact amounts of drug. Typically, however, epi-
ephrine vials and syringes are cheaper and allow for more accurate weight-based dosing. When needed, establish IV
access and start fluid resuscitation giving a dose of 10–
20mL/kg of normal saline over 5 to 10 min. Additionally,
high-flow supplemental oxygen (8–10 L/m) can be admi-
nistered through an infant face-mask. When available, the
infant should be hooked up to a continuous monitor for
respiratory rate, heart rate, oxygen saturations, and blood
pressure with an appropriately sized cuff.\textsuperscript{18} If indicated, start cardiopulmonary resuscitation per pediatric advance
life support guidelines. This includes giving thirty com-
pressions at a rate of 100–120/minute compressing one-
third the depth of the chest allowing complete recoil.\textsuperscript{34}
Epinephrine can be given every three to five minutes as
needed as this is first-line treatment. If infants with refrac-
tory anaphylaxis requiring multiple doses of epinephrine
or with significant cardiovascular or respiratory involve-
ment, an epinephrine infusion may be started. There is
some debate over the utility of additional antihistamines,
corticosteroids, or B-agonists and can be given if deemed
fit; however, these are not first-line agents and will not
rapidly reverse laryngeal edema, bronchospasm, or
hypotension. If an infant does not respond to initial ana-
phylaxis treatment, the infant should be transferred to
a pediatric emergency medicine team equipped in skilled
airway, ventilation, and optimal shock management. Once
the infant is stabilized, although rare, the infant should be
monitored for possible biphasic reaction.\textsuperscript{18}

Epinephrine is well tolerated in any age including
infants and has a reassuring safety profile. The mechanism
of action of epinephrine for use in treatment of anaphy-
laxis is that it works as a sympathomimetic agent increas-
ing bronchodilation, inotropy/chronotropy, vasoconstric-
tion, and decreasing mucosal edema.\textsuperscript{35} Thus,
it is effective in reversing laryngeal edema, hypotension,
and bronchoconstriction and downregulates mediators of
inflammation.\textsuperscript{35} Epinephrine can be given as either an
injection drawn up from an ampule or using an epineph-
rine auto-injector. The recommended epinephrine dose is
0.01mg/kg (max 0.3–0.5mg). The epinephrine auto-
jectors approved by the Food and Drug administration
currently available include 0.3mg, 0.15mg, and 0.1mg
dosages.\textsuperscript{36} Both 0.15mg and 0.3mg auto-injectors have ½
inch (14.7mm) needles. The estimated exposed needle
length of the 0.1mg is 0.29 inches (7.4 mm).\textsuperscript{36}

Prior to having the 0.1 mg autoinjector, there were two
concerns with using the 0.15 mg autoinjectors in infants: 1)
infants could receive an intrasosseous injection when using
the 14.7mm needle length devices and 2) infants could
receive a supratherapeutic epinephrine dose and this could
lead to adverse events.\textsuperscript{37} In a series of reports using ultra-
sound or MRI, Kim and Dreborg suggested that several
infants (estimated 43% in one study) would receive an
intrasosseous injection when using the available 0.15mg
devices.\textsuperscript{38–40} Substituting the 0.1mg device in these stu-
plies mitigated this risk. One must understand that these
studies simulated the experience and true intrasosseous
injection has never been shown and true risk is not
known. Therefore, based on needle length, it is reasonable
to prescribe the 0.1 mg to infants when available, but the
0.15 mg device can still be used.

Regarding the concern of supratherapeutic dosing, to the
authors’ knowledge, there are no known reports of adverse
cardiovascular outcomes of overdosing with epinephrine in
infants. In one succinct review on this topic, Brown
simulated percent of optimal dose of epinephrine for weight
using the various devices.\textsuperscript{36} While subjects under 10 kg
would receive at least 150% of the recommended dose (0.1 mg/kg),
and this reaches 200% at 7.5 kg, one must realize that once
the infant is >10kg, the clinician risks underdosing epinephrine if

---

**Figure 2** Treatment of infant anaphylaxis.

*Note: Data from Simons et al.\textsuperscript{14}*

---

1. Remove suspected trigger
2. Place patient in supine or semi-reclined position
3. Assess airway, breathing, circulation
4. Inject Epi IM (0.01mg/kg or use EAI)
   May repeat every 3-5 minutes
5. When available and/or if indicated, consider the following:
   - Place IV, continuous monitoring of vital signs, fluid resuscitation, oxygen administration, CPR.
   - Transfer to pediatric center if needed.
6. Monitor for biphasic reaction

---

---
the infant is prescribed the 0.1 mg device. In fact, based on current CDC growth curves, over 25% of 6-month-old infants would be expected to be over 10 kg, and thus even at 6 months, the clinician may underdose many children with the 0.1 mg device. Thus, when prescribing epinephrine autoinjectors in infants, clinicians must weigh the risks and benefits of which epinephrine device to prescribe and take each infant individually.

Finally, in addition to the above needle length and dose concerns, there is a risk of laceration due to using a long needle and jerking of the extremities by the patient. This risk is probably greater in older children who may be harder to hold still for an injection but exists for infants as well. There are holding techniques suggested, and it is important for clinicians to instruct parents and caregivers to make sure the infant is securely positioned with the leg held tight prior to injection.36

Periodic follow-up with an allergist is necessary for infants that have experienced anaphylaxis. The goal of long-term follow-up is to reassess previous allergic triggers/evaluate potential resolution, discuss any new allergic triggers, and discuss any barriers to appropriate treatment. Evaluating potential resolution can be followed by measuring serial skin prick or serum-specific IgE testing to specific triggers followed by diagnostic challenges if deemed warranted. Additionally, the epinephrine auto-injector should be adjusted based on patient’s weight. At each visit, continued education should be provided including how to properly avoid allergic triggers and how to administer epinephrine auto-injector if needed. It is also of benefit to review and provide families with a written anaphylaxis action plan.41,42

Future Directions
Although more information geared specifically towards infants has been published over the years, further research is still needed. Future directions include consideration of newer infant-specific diagnostic criteria as more data become available as well as more studies defining likely relevant co-morbidities and co-factors in this population. Additionally, using a more systematic way of analyzing these cases such as using multi-institutional studies would be helpful.

Given the likely increasing prevalence, infant anaphylaxis will be encountered. Thus, it is important to understand how to define, recognize, and treat infant anaphylaxis as outlined in this article.

Acknowledgment
The authors would like to thank Tamara Nelson, MLIS, EdS, AHIP for her contributions to this article.

Funding
No funding was received for this project.

Disclosure
Annette Carlisle has no conflicts of interests to report.

Jay Lieberman reports the following COI: Research support (money to institution) – Regeneron, DBV technologies, Aimimmune; Advisory Board Member (honorarium) – DBV technologies.

References


